Bacteremias and invasive fungal diseases in children receiving etanercept for steroid-resistant acute GVHD.
Faraci
M
M
Lanino
E
E
Morreale
G
G
Giardino
S
S
Fossati
M
M
Moroni
C
C
Caviglia
I
I
Castagnola
E
E
D000293:Adolescent; D016470:Bacteremia / Q000150:complications / Q000453:epidemiology*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004351:Drug Resistance; D000068800:Etanercept; D006086:Graft vs Host Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D009181:Mycoses / Q000150:complications / Q000453:epidemiology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D033581:Stem Cell Transplantation / Q000009:adverse effects
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept